| GEORGE MASON INTELLECTUAL PROPERTIES, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120321615 | Assay for Metastatic Colorectal Cancer - Disclosed herein is a method for predicting the prognosis, the likelihood of metastasis in, or the desirability of administering an aggressive therapy to, a subject with colorectal cancer, comprising determining, in a sample from the subject, the level of phosphorylation of one or more of certain proteins compared to a positive and/or negative reference standard; or the total amount of COX-2 protein compared to a positive and/or negative reference standard. Also described are methods for treating subjects likely to develop metastatic colorectal carcinoma, and pharmaceutical compositions and kits for implementing the methods of the invention. | 12-20-2012 |
| 20120086832 | Wearable Decorative Ornament With Visual Display - A wearable decorative ornament capable of photographing, storing and displaying an image, such that the image appears integral to the design of the decorative ornament, comprising a decorative case, an image-displaying device, an image capturing device, a communications port and a controller. | 04-12-2012 |
| 20120020328 | LABEL SWITCHED PACKET TRANSFER DEVICE - A device for connecting base station(s) to a cellular label switched network in a cellular network. The cellular network includes: base station(s), the connecting device(s); cellular label switched network(s); and service area(s). The base station(s) communicates with mobile terminals using wireless technology. The wireless technology uses a protocol layer architecture that includes at least one of the following: a wireless physical layer; a wireless medium access control protocol layer; a radio link control layer; and a network layer. The connecting device(s) include: a first interface to connect to the base station(s); a second interface to connect to cellular label switched network(s); and a label forwarding layer that: forwards packets between base station(s) and cellular label switched network(s); attaches label(s) to packets and removes label(s) from packets. A service area divided into a multitude of cells through which mobile terminals can move through and communicate with base station(s). | 01-26-2012 |
| 20120020292 | LABEL SWITCHED PACKET TRANSFER DEVICE - A device for connecting base station(s) to a cellular label switched network in a cellular network. The cellular network includes: base station(s), the connecting device(s); cellular label switched network(s); and service area(s). The base station(s) communicates with mobile terminals using wireless technology. The wireless technology uses a protocol layer architecture that includes at least one of the following: a wireless physical layer; a wireless medium access control protocol layer; a radio link control layer; and a network layer. The connecting device(s) include: a first interface to connect to the base station(s); a second interface to connect to cellular label switched network(s); and a label forwarding layer that: forwards packets between base station(s) and cellular label switched network(s); attaches label(s) to packets and removes label(s) from packets. A service area divided into a multitude of cells through which mobile terminals can move through and communicate with base station(s). | 01-26-2012 |
| 20110318336 | Identification and Treatment of Aggressive Lung Cancer Tumors - This invention relates to the identification and treatment of aggressive lung cancer tumors in patients. More particularly, it provides a method of identifying patients with non-small cell lung carcinoma (NSCLC) who have an aggressive node-negative (N0) tumor and a likelihood of a poor overall survival. The method comprises the step of determining if one or more of certain identified proteins are activated in tumor cells obtained from the patient's tumor, wherein the activation of one or more of the proteins indicates that the patient has an aggressive N0 tumor and is likely to have a poor overall-survival. The invention also provides a method for selecting a treatment for an NSCLC patient with an N0 tumor and a method for treating such patients. It further provides a kit for identifying an NSCLC patient with an aggressive N0 tumor and a likelihood of a poor overall survival and a pharmaceutical composition for treating such patients. | 12-29-2011 |
| 20110200597 | SIGNAL PATHWAY ALTERATIONS AND DRUG TARGET ELEVATIONS IN PRIMARY METACHRONOUS METASTATIC COLORECTAL CANCER COMPARED TO NON-METASTATIC DISEASE - The present invention relates to the identification and diagnostic use of biomarkers in primary colorectal cancer tumors whose activation level are predictive of the likelihood of the onset of metastatic disease. These biomarkers may be used to determine the suitability of a patient for aggressive and/or targeted treatments. Kits and compositions of the invention are also provided. | 08-18-2011 |
| 20110189173 | PHOSPHORYLATED C-ErbB2 AS A SUPERIOR PREDICTIVE THERANOSTIC MARKER FOR THE DIAGNOSIS AND TREATMENT OF CANCER - The present invention provides reliable methods to identify subsets of subjects with a cancer of epithelial origin characterized by a high level of phosphorylated c-erbB2 which does not correlate with the over-expression of total c-erbB2 as measured by IHC or FISH, for selection and inclusion for c-erbB2-direct treatment and therapy. Furthermore, the present invention provides a reliable method to determine whether a subject with a cancer of epithelial origin who has been determined to be c-erbB2 positive by IHC and by FISH should be excluded from c-erbB2-direct treatment because of a non-significant level of phosphorylated c-erbB2 in epithelial tumor tissue. | 08-04-2011 |
| 20110054303 | Apparatus for registering and tracking an instrument - There is provided a device for generating a frame of reference and tracking the position and orientation of a tool in computer-assisted image guided surgery or therapy system. A first curvature sensor including fiducial markers is provided for positioning on a patient prior to volumetric imaging, and sensing the patient's body position during surgery. A second curvature sensor is coupled to the first curvature sensor at one end and to a tool at the other end to inform the computer-assisted image guided surgery or therapy system of the position and orientation of the tool with respect to the patient's body. A system is provided that incorporates curvature sensors, a garment for sensing the body position of a person, and a method for registering a patient's body to a volumetric image data set in preparation for computer-assisted surgery or other therapeutic interventions. This system can be adapted for remote applications as well. | 03-03-2011 |
| 20110046039 | POST-EXPOSURE PROPHYLAXIS AND TREATMENT OF INFECTIONS - The invention provides methods and materials for identifying agents for preventing and/or treating anthrax and similar diseases. Embodiments provide strains and model systems for studying non-lethal and lethal exposure to anthrax and similar disease vectors. Embodiments provide materials and methods for using the strains and model systems for differential profiling, such as proteomic profiling, such as differentiation phosphorylation profiling, to target identification and therapeutics discovery and development. Embodiments provide pharmaceutically acceptable compositions, and methods for using them to prevent and/or treat anthrax and similar diseases comprising an agent that decreases the activity of caspase ΒΌ, such as YVAD, and/or an agent that increases the phosphorylation of AKT, such as IB-MECA or Cl-IB-MECA, together with, in particular embodiments, an antibiotic, such as ciprofloxacin. Kits comprising the same are provided as well, among other things. | 02-24-2011 |
| 20100298157 | PHOSPHOPROTEOMIC EVALUATION OF DIABETES AND OBESITY - A subject's likelihood of responding to bariatric surgery can be assessed by measuring the phosphorylation state of certain proteins found in white adipose tissue (WAT). In particular, measuring the phosphorylation state of particular proteins can predict a patient's likelihood of resolving diabetes mellitus following bariatric surgery. In addition, evaluating the phosphorylation state of certain proteins forecasts a patient's capacity to reduce excess body weight and/or waist size following bariatric surgery. Such tests are valuable tools for managing the diseases of diabetes and obesity and determining who would most likely benefit from bariatric surgical procedures such as gastic bypass surgery. | 11-25-2010 |
| 20100159486 | BIOMARKERS FOR NEUROLOGICAL CONDITIONS - Low molecular weight (LMW) peptides have been discovered that are indicative of neurological conditions, such as Alzheimer's Disease (AD), cognitive impairment and brain microhemmorhages. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting neurological conditions and monitoring the progression of the disease. The LMW peptides are particularly useful in detecting neurological conditions during the early stages without invasive procedures. | 06-24-2010 |
| 20100143949 | BIOMARKERS FOR COLORECTAL CANCER - Low molecular weight (LMW) peptides have been discovered that are indicative of colorectal cancer. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting colorectal cancer and monitoring the progression of the disease. The LMW peptides are particularly useful in detecting colorectal cancer during its early stages. | 06-10-2010 |
| 20100068690 | TISSUE PRESERVATION AND FIXATION METHOD - This invention relates, e.g., to a composition that, at room temperature, when contacted with a sample comprising phosphoproteins, can fix and stabilize cellular phosphoproteins, preserve cellular morphology, and allow the sample to be frozen to generate a cryostat frozen section suitable for molecular analysis. The composition comprises (1) a fixative that is effective to fix the phosphoproteins, and that has a sufficient water content to be soluble for a stabilizer and/or a permeability enhancing agent); (2) a stabilizer, comprising (a) a kinase inhibitor and (b) a phosphatase inhibitor and, optionally, (c) a protease (e.g., proteinase) inhibitor; and (3) a permeability enhancing agent (e.g. PEG). Methods are described for preserving phosphoproteins, using such a composition. Also described are endogenous surrogate markers for monitoring protein degradation, including the loss of posttranslational modifications (such as phosphorylation), e.g. the following removal of a cell or tissue from a subject; and exogenous molecular sentinels (e.g. phosphoproteins attached to magnetic nanoparticles) that allow one to evaluate the processing history of a cellular or tissue population sample. | 03-18-2010 |
| 20100034729 | Iron Composition Based Water Filtration System for the Removal of Chemical Species Containing Arsenic and other Metal Cations and Anions - An iron composition having a plurality of elemental components is disclosed. The major component is an iron component of at least about 68% to about 92% iron by weight. Other components by weight include manganese; cerium; carbon; phosphorous; sulfur; aluminum; silicon; chromium; copper; and zinc. Combined with layers of sand, brick chips and/or charcoal, the iron composition can be used to create a water filter for filtering inorganic arsenic species and soluble metal ions out of water. To enhance hydrous ferric oxide complexation and precipitation, the iron composition may be treated with food grade acids or a water mixture. | 02-11-2010 |
| 20100003247 | ASSAY FOR METASTATIC COLORECTAL CANCER - This invention relates, e.g., to a method for predicting the prognosis, the likelihood of metastasis in, or the desirability of administering an aggressive therapy to, a subject with colorectal cancer, comprising determining, in a sample from the subject, the level of phosphorylation compared to a positive and/or negative reference standard, of one or more of: (a) AKT (S473); (b) BAD (S112); (c) cABL (T735); (d) ERK (T42/44); (e) MARCKS (S152-156); (0 p38MAPK (T180-182): (g) STAT 1 (Y701 ); (h) PTEN (S380); (i) EGFR (Y992); (j) PAK 1/2 (S 1 19/204); or (k) PKC zeta/lambda (T410-403); or the total amount of (1) COX-2 protein; wherein if the level of phosphorylation of one or more of a-i or the total amount of COX-2 protein (1) is elevated compared to the negative reference standard, and/or if the level of phosphorylation of j or k is decreased compared to the positive reference standard, the subject has poor prognosis, is likely to undergo metastasis, and/or is a good candidate for aggressive therapy. Also described are methods for treating subjects likely to develop metastatic colorectal carcinoma, and pharmaceutical compositions and kits for implementing methods of the invention. | 01-07-2010 |
| 20080311593 | METHODS OF DIAGNOSING NON-ALCOHOLIC STEATOHEPATITIS (NASH) - Non-invasive methods for detecting non-alcoholic fatty liver disease (NAFLD) and identifying the presence or absence of non-alcoholic steatohepatitis (NASH) in a subject utilize one or more biomarkers. The methods can differentiate between subjects with NASH and those with simple steatosis. Kits containing one or more agents for measuring the level of the biomarkers can be utilized to perform the described methods. | 12-18-2008 |
